Limited benefits and notable harms

Madeleine Finlay sits down with co-host and science editor Ian Sample to discuss three eye-catching stories from the week, including a review into the effectiveness of a new class of Alzheimer’s drug that was once hailed as a game-changer in slowing the progress of the disease. Also on the agenda is the news that the world could be heading for a ‘super El Niño’ this summer and a study exploring whether conversations about dull topics really are as boring as we expect them to be. Help support our independent journalism at theguardian.com/sciencepod